Antihypertensive treatment inhibiting the progression of diabetic nephropathy

Area of Science:

• Nephrology
• Diabetology
• Pharmacology

Background:

• Diabetic nephropathy is a major complication of diabetes mellitus.
• Proteinuria and declining glomerular filtration rate (GFR) are key indicators of nephropathy progression.
• Managing hypertension is crucial in diabetic patients to prevent cardiovascular and renal complications.

Purpose of the Study:

• To evaluate the effect of antihypertensive therapy on the progression of nephropathy in male insulin-dependent diabetics.
• To assess the impact of a specific drug combination (beta-blocker, Hydralazine, Furosemide) on GFR and albuminuria.

Main Methods:

• Longitudinal study of 6 male diabetic patients with nephropathy over 6.1 years (2.0 years control, 4.1 years treatment).
• Regular measurements of GFR and urinary albumin excretion before and during antihypertensive treatment.
• Statistical analysis of blood pressure, GFR, and albumin excretion changes.

Main Results:

• Significant reduction in systolic (162 to 146 mmHg) and diastolic (103 to 95 mmHg) blood pressure during treatment.
• Significant decrease in albumin clearance relative to GFR (0.243 to 0.170) after 49 days.
• Reduced rate of GFR decline from 1.24 to 0.45 ml/min/month during antihypertensive therapy (p=0.037).
• Yearly increase in albumin excretion reduced from 107% to -7% (p=0.002).

Conclusions:

• Antihypertensive treatment, including a beta-blocker, Hydralazine, and Furosemide, can significantly slow the progression of diabetic nephropathy.
• This therapeutic approach may postpone the onset or worsening of renal insufficiency in diabetic patients with hypertension.
• Further trials are needed to determine optimal antihypertensive regimens for diabetic nephropathy.